Literature DB >> 20924115

Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis.

Sabina Sangaletti1, Claudio Tripodo, Chiara Ratti, Silvia Piconese, Rossana Porcasi, Rosalba Salcedo, Giorgio Trinchieri, Mario P Colombo, Claudia Chiodoni.   

Abstract

Oncogene activation promotes an intrinsic inflammatory pathway that is crucial for cancer development. Here, we have investigated the actual effect of the inflammatory cytokine tumor necrosis factor (TNF) on the natural history of spontaneous mammary cancer in the HER2/neuT (NeuT) transgenic mouse model. Bone marrow transplantation from TNF knockout mice into NeuT recipients significantly impaired tumor growth, indicating that the source of TNF fostering tumor development was of bone marrow origin. We show that the absence of leukocyte-derived TNF disarranged the tumor vasculature, which lacked pericyte coverage and structural integrity, leading to diffuse vascular hemorrhage and stromal necrosis. In addition, tumor-associated Tie2-expressing monocytes were reduced and cytokine expression skewed from Th2 to Th1 type. Treatment of NeuT mice with anti-TNF antibody partially phenocopied the antitumor effect of TNF-deficient bone marrow cell transplantation, providing a strong preclinical background and rationale for the introduction of TNF antagonists in the treatment of human breast cancer, including basal-like samples for which consolidated targeted therapies do not exist. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924115      PMCID: PMC7371347          DOI: 10.1158/0008-5472.CAN-10-0471

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

Review 1.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

Authors:  Frances Balkwill; Kellie A Charles; Alberto Mantovani
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

2.  Altered retinal neovascularization in TNF receptor-deficient mice.

Authors:  Ron C Ilg; Michael H Davies; Michael R Powers
Journal:  Curr Eye Res       Date:  2005-11       Impact factor: 2.424

Review 3.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cell Cycle       Date:  2009-04-04       Impact factor: 4.534

4.  A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

Authors:  Srinivasan Madhusudan; Martin Foster; Sethupathi R Muthuramalingam; Jeremy P Braybrooke; Susan Wilner; Kulwinder Kaur; Cheng Han; Susan Hoare; Frances Balkwill; Denis C Talbot; Trivadi S Ganesan; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

5.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis.

Authors:  Boryana K Popivanova; Kazuya Kitamura; Yu Wu; Toshikazu Kondo; Takashi Kagaya; Shiuchi Kaneko; Masanobu Oshima; Chifumi Fujii; Naofumi Mukaida
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

6.  Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice.

Authors:  F Lucchini; M G Sacco; N Hu; A Villa; J Brown; L Cesano; L Mangiarini; G Rindi; S Kindl; F Sessa
Journal:  Cancer Lett       Date:  1992-07-10       Impact factor: 8.679

7.  Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration.

Authors:  Ryoichi Mori; Toshikazu Kondo; Tohru Ohshima; Yuko Ishida; Naofumi Mukaida
Journal:  FASEB J       Date:  2002-07       Impact factor: 5.191

8.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.

Authors:  G-One Ahn; J Martin Brown
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

9.  CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis.

Authors:  Claudio Tripodo; Andrea Di Bernardo; Maria Paola Ternullo; Carla Guarnotta; Rossana Porcasi; Sabrina Ingrao; Umberto Gianelli; Emanuela Boveri; Emilio Iannitto; Giovanni Franco; Ada Maria Florena
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

Review 10.  Tumour necrosis factor-alpha as a tumour promoter.

Authors:  Peter Szlosarek; Kellie A Charles; Frances R Balkwill
Journal:  Eur J Cancer       Date:  2006-03-06       Impact factor: 9.162

View more
  21 in total

1.  Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures.

Authors:  Tal Leibovich-Rivkin; Yulia Liubomirski; Biana Bernstein; Tsipi Meshel; Adit Ben-Baruch
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 2.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

3.  The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines.

Authors:  Adit Ben-Baruch
Journal:  Cancer Microenviron       Date:  2011-12-22

Review 4.  Cancer and inflammation.

Authors:  Lance L Munn
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-12-12

5.  Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.

Authors:  Uciane K Scarlett; Jose R Conejo-Garcia
Journal:  Expert Rev Obstet Gynecol       Date:  2012-09-01

Review 6.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

7.  Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.

Authors:  Krissa Gibby; Weon-Kyoo You; Kuniko Kadoya; Hildur Helgadottir; Lawrence Jt Young; Lesley G Ellies; Yunchao Chang; Robert D Cardiff; William B Stallcup
Journal:  Breast Cancer Res       Date:  2012-04-24       Impact factor: 6.466

8.  2011: the immune hallmarks of cancer.

Authors:  Federica Cavallo; Carla De Giovanni; Patrizia Nanni; Guido Forni; Pier-Luigi Lollini
Journal:  Cancer Immunol Immunother       Date:  2011-01-26       Impact factor: 6.968

9.  Inhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer.

Authors:  Julia Inglés-Esteve; Mònica Morales; Alba Dalmases; Ricard Garcia-Carbonell; Alba Jené-Sanz; Núria López-Bigas; Mar Iglesias; Cristina Ruiz-Herguido; Ana Rovira; Federico Rojo; Joan Albanell; Roger R Gomis; Anna Bigas; Lluís Espinosa
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

Review 10.  Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.

Authors:  Michel DuPage; Tyler Jacks
Journal:  Curr Opin Immunol       Date:  2013-03-04       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.